ClassID:

170262

G01N2333/163 - CPC Classification

Classification description:

Assays involving biological materials from specific organisms or of a specific nature from viruses; RNA viruses; Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus; Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV; HIV-1, HIV-2 Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx

Recent Application in this class:
#1
20220252600
2022-08-11

EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES

#2
20210405029
2021-12-30

Compounds inhibiting Nef-calnexin interaction

#3
20200340977
2020-10-29

Compounds inhibiting Nef-calnexin interaction

#4
20200338067
2020-10-29

CAMPTOTHECIN DERIVATIVES AS ANTI-HIV AGENTS AND METHODS OF IDENTIFYING AGENTS THAT DISRUPT VIF SELF-ASSOCIATION

#5
20200033343
2020-01-30

Exosome-mediated diagnosis of human immunodeficiency virus infection

#6
20190346443
2019-11-14

Exosome-mediated diagnosis of hepatitis virus infections and diseases

#7
20190033297
2019-01-31

Compounds inhibiting Nef-calnexin interaction

#8
20180228918
2018-08-16

Silica-based biomolecule carrier, pharmaceutical composition comprising the same, preparation method and use thereof

#9
20170299591
2017-10-19

EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES

#10
20170168052
2017-06-15

Exosome-mediated diagnosis of hepatitis virus infections and diseases

#11
20170010264
2017-01-12

Exosome-mediated diagnosis of hepatitis virus infections and diseases

#12
20160143900
2016-05-26

Camptothecin derivatives as anti-HIV agents and methods of identifying agents that disrupt Vif self-association

#13
20150272959
2015-10-01

SMALL MOLECULES AS ANTI-HIV AGENTS THAT DISRUPT VIF SELF-ASSOCIATION AND METHODS OF USE THEREOF

#14
20150268247
2015-09-24

Assay for Screening of Anti-Viral Compounds That Inhibit Specific Interaction Interfaces Between Cullin5 and an ElonginB/ElonginC/ CBF-beta/HIV-1 Vif Complex

#15
20150125850
2015-05-07

Dual inducible vectors and cell lines

#16
20140134606
2014-05-15

Exosome-mediated diagnosis of hepatitis virus infections and diseases

#17
20130109028
2013-05-02

Vector, vector combinations, methods and kit thereof

#18
20120214151
2012-08-23

Detection of HIV-related proteins in urine

#19
20120208175
2012-08-16

Detection of HIV-related proteins in urine

#20
20120108500
2012-05-03

Compositions and Methods for Modulating Immunodeficiency Virus Transcription

#21
20110236409
2011-09-29

OVERLAPPING PEPTIDES FROM VARIABLE ANTIGENS, T CELL POPULATIONS AND USES THEREOF

#22
20110212030
2011-09-01

Nucleic acid ligand complexes

#23
20110195078
2011-08-11

TAT-BASED IMMUNOMODULATORY COMPOSITIONS AND METHODS FOR THEIR DISCOVERY AND USE

#24
20110152301
2011-06-23

Compounds that Inhibit HIV Particle Formation

#25
20100261751
2010-10-14

METHOD FOR DETERMINING ONE OF THE TWO HUMAN IMMUNODEFICIENCY VIRUS (HIV) INTEGRASE ENZYMATIC ACTIVITIES

#26
20100086956
2010-04-08

Detection of HIV-related proteins in urine

#27
20090118481
2009-05-07

High Affinity Nucleic Acid Ligands To Lectins

#28
20090117155
2009-05-07

TREATMENT OF HIV-1 BY MODULATION OF VPR ACTIVATION OF THE M-CSF PROMOTER

#29
20080318959
2008-12-25

Compounds that inhibit HIV particle formation

#30
20080293036
2008-11-27

Monoclonal antibodies to HIV-1 and methods of using same

#31
20080269537
2008-10-30

METAL BINDING PROTEINS AND ASSOCIATED METHODS

#32
20080220008
2008-09-11

Mutated HIV Nef for modulating immunity

#33
20080155703
2008-06-26

Tat-based immunomodulatory compositions and methods of their discovery and use

#34
20070134767
2007-06-14

Hiv-dependent expression constructs and uses therefor

#35
20070117968
2007-05-24

Metal binding proteins and associated methods

#36
20070092939
2007-04-26

HUMAN IMMUNODEFICIENCY VIRUS ENTRY INHIBITOR ASSAY

#37
20070021327
2007-01-25

Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor

#38
20060252075
2006-11-09

Method for monitoring anti-HIV treatment in HIV infected individuals

#39
20060241150
2006-10-26

P38 kinase inhibitor compositions and methods of using the same

#40
20060105378
2006-05-18

Tenascin-C nucleic acid ligands

#41
20060088877
2006-04-27

Systematic evolution of ligands by exponential enrichment: Chemi-SELEX

#42
20060084797
2006-04-20

High affinity TGFbeta nucleic acid ligands and inhibitors

#43
20060052326
2006-03-09

Werner's syndrome helicase as a target for anti -HIV/AIDS therapy

#44
20060052285
2006-03-09

Screening methods for the identification of inhibitors of human immunodeficiency virus (HIV) viral protein R (Vpr) binding to the adenine nucleotide translocator (ANT)

#45
20050245454
2005-11-03

Methods and compositions for impairing multiplication of HIV-1

#46
20050214751
2005-09-29

Inhibition of viral maturation, methods and compositions related thereto

#47
20050208482
2005-09-22

Tat-based immunomodulatory compositions and methods for their discovery and use

#48
20050164974
2005-07-28

Nucleic acid ligand complexes

#49
20050136474
2005-06-23

Truncation SELEX method

#50
20050112562
2005-05-26

Inhibition of retroviral replication through modulation of the host cell ubiquitylation

#51
20050043265
2005-02-24

High affinity RNA ligands of basic fibroblast growth factor

#52
20050026138
2005-02-03

HIV-1 VPR interactions with mitochondrial apoptosis inducing factor and methods of using the same